Market Intelligence, Clinical Progress, and High-Purity Reagents for ISR Modulation and Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EIF2AK4 (GCN2) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Kinase) | EIF2AK4 Kinase Domain (Active) High purity (>95%), ATP-binding site intact. Sequence Verified. Theoretical MW. |
View EIF2AK4 Products |
| Substrate | EIF2S1 (eIF2α) WT and Ser51Ala Mutant For kinase activity and phospho-specificity assays. Endotoxin Controlled. |
View EIF2S1 Products |
| Gene Delivery | EIF2AK4 Promise-ORF / Lentivirus Full-length ORF for stable ISR reporter cell lines. HEK293 Expressed. |
View EIF2AK4 Products |
| Benchmark Ab | Anti-EIF2AK4 (Phospho-Thr899/Thr947) Detects activated kinase conformation. Recombinant. |
View EIF2AK4 Products |
| Validator | EIF2AK4 siRNA Set For knockdown verification and pathway specificity controls. |
View EIF2AK4 Products |
| Selectivity Control 1 | EIF2AK1 (HRI) Kinase Domain Paralog eIF2α kinase for selectivity screening (avoid off-target hematologic effects). |
View EIF2AK1 Products |
| Selectivity Control 2 | EIF2AK3 (PERK) Kinase Domain ER stress kinase for off-target liability testing (pancreatic/ER stress selectivity). |
View EIF2AK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATP-Competitive Inhibitor Screening (Need active kinase conformation) | High Purity (>95%) Active Kinase Domain with verified ATP-binding pocket. Sequence Verified. |
| Selectivity vs. eIF2α Kinase Family (PERK, HRI, PKR) | Ortholog Panel: EIF2AK1, EIF2AK2, EIF2AK3 Kinase Domains. Strictly verified by Mass Spec. |
| Substrate Phosphorylation Validation | Recombinant EIF2S1 (Ser51) and phospho-deficient mutant (Ser51Ala) as negative control. |
| Cellular ISR Pathway Modulation | Lentivirus Premade Particles for stable ATF4-reporter cell line construction. |
| Compound Penetration (CNS/Intracellular) | Cell-based phospho-eIF2α assays using TarMart lentivirus-transduced lines. |
Live EIF2AK4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EIF2AK4 (GCN2) modulation is bifurcating into two strategic directions: inhibition for cancer immunotherapy and amino acid deprivation strategies, and activation for hemoglobinopathies and pulmonary arterial hypertension (PAH). As first-generation ATP-competitive inhibitors enter clinical evaluation, the next wave of R&D is targeting allosteric modulators and brain-penetrant compounds for neurodegenerative indications involving the Integrated Stress Response (ISR).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Calico, AbbVie, Biotech startups | Solid Tumors, ALS/FTD | ATP Competition & Selectivity Panel (Need EIF2AK1/AK3 for counter-screening) |
| Activators/Agonists | Global Blood Therapeutics, Academic labs | Sickle Cell Disease, PAH | ATF4 Reporter Assay (Need high-expression lentivirus) |
| PROTAC Degraders | Emerging platforms | Refractory Tumors | Intracellular Target Engagement (Need active kinase antigen for ternary complex formation) |
| Antisense Oligonucleotides | Ionis Pharma (exploratory) | Neurodegeneration | Knockdown Validation (Need validated siRNA controls) |